Tabimorelin

Growth Hormone Secretagogue (GHS) / Ghrelin Receptor AgonistRx: ResearchCompound: Investigational

Also known as: Ipamorelin analog (non-peptide), NN703, Tabimorelin hydrate

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Tabimorelin is an orally active, non-peptide growth hormone secretagogue that acts as a GHS-R1a agonist. It was developed as a potential treatment for GH deficiency and was investigated for its ability to stimulate GH release, improve body composition, and as a diagnostic tool for GH deficiency. Clinical development was discontinued, and it has not received regulatory approval in any major jurisdiction.

Mechanism of Action

Selective agonist of the growth hormone secretagogue receptor (GHS-R1a / ghrelin receptor), stimulating pulsatile release of growth hormone from the anterior pituitary and hypothalamus.

Routes of Administration

Oral

Goals & Uses

  • Diagnostic testing for GH deficiencyDiagnosticsModerate
  • Growth hormone deficiency (GHD) treatmentEndocrinologyModerate
  • IGF-1 elevationMetabolic / HormonalModerate
  • Body composition improvementMetabolicLow

Contraindications

  • Active malignancyOncologyHighUse caution or avoid depending on agent and context
  • Hypersensitivity to tabimorelinAllergy/ImmunologyHigh
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Proliferative or severe non-proliferative diabetic retinopathyOphthalmologyHigh

Adverse Effects

  • Elevated blood glucose / insulin resistanceMetabolicUncommon
  • Edema / fluid retentionMetabolicUncommon
  • Increased appetite / hungerGastrointestinal / MetabolicCommon
  • Cortisol elevationEndocrinologyUncommon
  • Arthralgia / myalgiaMusculoskeletalUncommon

Drug Interactions

  • GlucocorticoidsModerate
  • Insulin / antidiabetic agentsModerate
  • Somatostatin analogues (e.g., octreotide)High

Population Constraints

  • Pediatric patientsAgeRelative
  • Patients with diabetes mellitusMetabolicRelative
  • Elderly patientsAgeRelative
  • Patients with History of MalignancyOncologyRelative

Regulatory Status

  • European UnionInvestigationalNever received EMA approval; Phase II/III trials conducted but development halted.
  • United StatesInvestigationalNever received FDA approval; clinical development discontinued by Novo Nordisk.
  • United KingdomInvestigationalNo MHRA approval; research compound only.

Tabimorelin was investigated in Phase II/III clinical trials but was never approved by FDA, EMA, or other major regulatory bodies. Development was discontinued; it remains a research compound.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack